Objection To analyze the relationship between blood type and prognosis of colorectal cancer patients in the Database from Colorectal Cancer (DACCA). Methods The DACCA version selected for this data analysis was updated on January 5, 2022. The data items analysis included age, gender, blood type, tumor location, tumor pathological nature, pathological TNM (pTNM) stage, survival status and survival time. According to the ABO blood type classification, it was divided into four blood type groups: A blood type group, B blood type group, AB blood type group, and O blood type group. The overall survival (OS) and disease specific survival (DSS) were analyzed in four blood type groups, and the OS and DSS of each blood type group were analyzed in pTNM stage stratification. Results A total of3 486 rows of data were obtained from the DACCA database according to the screening conditions. There was no significantdifference in OS and DSS among blood typy A, B, AB and O group (P>0.05); At specific time points, the 1-year OS of the blood type A group was worse than that of blood type B (95.8% vs. 99.6%), the 1-year OS of the blood type B group was better than that of blood type O group (99.6% vs. 96.9%), and the differences were statistically significant (P<0.008 7), but the differences between OS and DSS in the remaining 1, 3, 5 and 10 years of patients with different blood type groups were not statistically significant (P>0.008 7). In each pTNM staging subgroup, the differences between 1, 3, 5 and 10-year OS and DSS were not statistically significant among different blood type groups (P>0.008 7). Conclusions Overall, there was no significant difference in prognosis among the blood type A, B, AB, and O groups. Comparing specific blood types and follow-up time, patients with blood type B have slightly better 1-year OS than patients with blood type A or blood type O. Comparisons between other ABO blood groups and between ABO blood groups classified by the pTNM staging subgroup did not show a difference.
Objective To systematically evaluate risk prediction models for acute exacerbation of chronic obstructive pulmonary disease (COPD), and provide a reference for early clinical identification. Methods The literature on the risk prediction models of acute exacerbation of COPD published by CNKI, VIP, Cochrane, Embase and Web of Science database was searched in Chinese and English from inception to April 2022, and relevant studies were collected on the development of risk prediction models for acute exacerbations of COPD. After independent screening of the literature and extraction of information by two independent researchers, the quality of the included literature was evaluated using the PROBASTA tool. Results Five prospective studies, one retrospective case-control study and seven retrospective cohort studies were included, totally 13 papers containing 24 models. Twelve studies (92.3%) reported the area under the receiver operator characteristic curve ranging 0.66 to 0.969. Only five studies reported calibrated statistics, and three studies were internally and externally validated. The overall applicability of 13 studies was good, but there was a high risk of bias, mainly in the area of analysis. Conclusions The existing predictive risk models for acute exacerbations of COPD are unsatisfactory, with wide variation in model performance, inappropriate and incomplete inclusion of predictors, and a need for better ways to develop and validate high-quality predictive models. Future research should refine the study design and study report, and continue to update and validate existing models. Secondly medical staff should develop and implement risk stratification strategies for acute exacerbations of COPD based on predicted risk classification results in order to reduce the frequency of acute exacerbations and to facilitate the rational allocation of medical resources.